Retatrutide (LY3437943) is a synthetic peptide investigated as a molecular research tool for studying three receptor systems: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.<\/p>\n
Its triple-receptor agonist profile allows researchers to examine interactions among these signaling pathways within controlled experimental models.<\/p>\n
This material is supplied exclusively for laboratory research and analytical applications.<\/p>\n
Specifications<\/b><\/strong><\/p>\n Product Classification:<\/b><\/strong>\u00a0Research Use Only (RUO) Research Applications<\/b><\/strong><\/p>\n Retatrutide may be used in controlled laboratory models investigating:<\/p>\n Warning<\/b><\/strong><\/p>\n FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT FOR HUMAN CONSUMPTION.<\/b><\/strong><\/p>\n This product is intended solely for qualified laboratory research and analytical applications.<\/p>\n Scientific Report<\/b><\/strong><\/p>\n Abstract<\/b><\/strong><\/p>\n Retatrutide is a synthetic peptide characterized experimentally by agonist activity across GIP, GLP-1, and glucagon receptors. This triple-receptor profile provides a molecular model for examining the simultaneous activation and interaction of three distinct receptor pathways.<\/p>\n Mechanistic Pathways<\/b><\/strong><\/p>\n GIP Receptor<\/b><\/strong><\/p>\n Retatrutide exhibits agonist activity at the GIP receptor.<\/p>\n Research focus:<\/b><\/strong>\u00a0Receptor activation and downstream GIP-associated signaling.<\/p>\n GLP-1 Receptor<\/b><\/strong><\/p>\n GLP-1 receptor activity represents a second component of the compound’s experimental pharmacological profile.<\/p>\n Research focus:<\/b><\/strong>\u00a0GLP-1 receptor activation and associated intracellular signaling.<\/p>\n Glucagon Receptor<\/b><\/strong><\/p>\n Retatrutide also interacts with the glucagon receptor.<\/p>\n Research focus:<\/b><\/strong>\u00a0Glucagon-receptor activation and downstream pathway analysis.<\/p>\n Triple-Receptor Interaction<\/b><\/strong><\/p>\n The defining characteristic of retatrutide as a research compound is the ability to examine three receptor systems using a single molecular platform.<\/p>\n Research focus:<\/b><\/strong>\u00a0Interactions among GIP, GLP-1, and glucagon receptor pathways.<\/p>\n Research Profile<\/b><\/strong><\/p>\n Compound:<\/b><\/strong>\u00a0Retatrutide \/ LY3437943 Research Parameters<\/b><\/strong><\/p>\n Experimental concentrations, assay conditions, exposure periods, controls, and endpoints should be selected according to the laboratory model and validated research protocol being used.<\/p>\n No instructions for human or veterinary use are provided.<\/p>\n Research Highlights<\/b><\/strong><\/p>\n Conclusion<\/b><\/strong><\/p>\n Retatrutide provides researchers with a molecular tool for studying simultaneous GIP, GLP-1, and glucagon receptor activity and interactions among these pathways under controlled experimental conditions.<\/p>\n","protected":false},"excerpt":{"rendered":" Retatrutide (LY3437943) is a synthetic peptide investigated as a molecular research tool for studying three receptor systems: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.<\/p>\n Its triple-receptor agonist profile allows researchers to examine interactions among these signaling pathways within controlled experimental models.<\/p>\n This material is supplied exclusively for laboratory research and analytical applications.<\/p>\n Specifications<\/b><\/strong><\/p>\n Product Classification:<\/b><\/strong>\u00a0Research Use Only (RUO) Research Applications<\/b><\/strong><\/p>\n Retatrutide may be used in controlled laboratory models investigating:<\/p>\n Warning<\/b><\/strong><\/p>\n FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT FOR HUMAN CONSUMPTION.<\/b><\/strong><\/p>\n This product is intended solely for qualified laboratory research and analytical applications.<\/p>\n Scientific Report<\/b><\/strong><\/p>\n Abstract<\/b><\/strong><\/p>\n Retatrutide is a synthetic peptide characterized experimentally by agonist activity across GIP, GLP-1, and glucagon receptors. This triple-receptor profile provides a molecular model for examining the simultaneous activation and interaction of three distinct receptor pathways.<\/p>\n Mechanistic Pathways<\/b><\/strong><\/p>\n GIP Receptor<\/b><\/strong><\/p>\n Retatrutide exhibits agonist activity at the GIP receptor.<\/p>\n Research focus:<\/b><\/strong>\u00a0Receptor activation and downstream GIP-associated signaling.<\/p>\n GLP-1 Receptor<\/b><\/strong><\/p>\n GLP-1 receptor activity represents a second component of the compound’s experimental pharmacological profile.<\/p>\n Research focus:<\/b><\/strong>\u00a0GLP-1 receptor activation and associated intracellular signaling.<\/p>\n Glucagon Receptor<\/b><\/strong><\/p>\n Retatrutide also interacts with the glucagon receptor.<\/p>\n Research focus:<\/b><\/strong>\u00a0Glucagon-receptor activation and downstream pathway analysis.<\/p>\n Triple-Receptor Interaction<\/b><\/strong><\/p>\n The defining characteristic of retatrutide as a research compound is the ability to examine three receptor systems using a single molecular platform.<\/p>\n Research focus:<\/b><\/strong>\u00a0Interactions among GIP, GLP-1, and glucagon receptor pathways.<\/p>\n Research Profile<\/b><\/strong><\/p>\n Compound:<\/b><\/strong>\u00a0Retatrutide \/ LY3437943 Research Parameters<\/b><\/strong><\/p>\n Experimental concentrations, assay conditions, exposure periods, controls, and endpoints should be selected according to the laboratory model and validated research protocol being used.<\/p>\n No instructions for human or veterinary use are provided.<\/p>\n Research Highlights<\/b><\/strong><\/p>\n Conclusion<\/b><\/strong><\/p>\n Retatrutide provides researchers with a molecular tool for studying simultaneous GIP, GLP-1, and glucagon receptor activity and interactions among these pathways under controlled experimental conditions.<\/p>\n","protected":false},"featured_media":105,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[16],"product_tag":[],"class_list":["post-12","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic","first","instock","featured","shipping-taxable","purchasable","product-type-variable"],"acf":[],"_links":{"self":[{"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product\/12","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/comments?post=12"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/media\/105"}],"wp:attachment":[{"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/media?parent=12"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product_brand?post=12"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product_cat?post=12"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/th.webtestsdev.com\/cdxcompounds\/wp-json\/wp\/v2\/product_tag?post=12"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nCompound:<\/b><\/strong>\u00a0Retatrutide (LY3437943)
\nAvailable Content:<\/b><\/strong>\u00a010 mg or 30 mg per vial
\nClassification:<\/b><\/strong>\u00a0GIP \/ GLP-1 \/ Glucagon receptor agonist
\nForm:<\/b><\/strong>\u00a0Lyophilized research material
\nPackaging:<\/b><\/strong>\u00a0Research vial
\nPurity:<\/b><\/strong>\u00a0\u226599% (include only when confirmed by the applicable batch COA)<\/i><\/em>
\n<\/i><\/em>Intended Use:<\/b><\/strong>\u00a0Laboratory research and analytical purposes only<\/p>\n\n
\nClassification:<\/b><\/strong>\u00a0Triple-receptor agonist
\nPrimary Research Areas:<\/b><\/strong>\u00a0GIP, GLP-1, and glucagon receptor signaling
\nResearch Setting:<\/b><\/strong>\u00a0Controlled laboratory and preclinical models<\/p>\n\n
\nCompound:<\/b><\/strong>\u00a0Retatrutide (LY3437943)
\nAvailable Content:<\/b><\/strong>\u00a010 mg or 30 mg per vial
\nClassification:<\/b><\/strong>\u00a0GIP \/ GLP-1 \/ Glucagon receptor agonist
\nForm:<\/b><\/strong>\u00a0Lyophilized research material
\nPackaging:<\/b><\/strong>\u00a0Research vial
\nPurity:<\/b><\/strong>\u00a0\u226599% (include only when confirmed by the applicable batch COA)<\/i><\/em>
\n<\/i><\/em>Intended Use:<\/b><\/strong>\u00a0Laboratory research and analytical purposes only<\/p>\n\n
\nClassification:<\/b><\/strong>\u00a0Triple-receptor agonist
\nPrimary Research Areas:<\/b><\/strong>\u00a0GIP, GLP-1, and glucagon receptor signaling
\nResearch Setting:<\/b><\/strong>\u00a0Controlled laboratory and preclinical models<\/p>\n\n